JP2019519581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519581A5 JP2019519581A5 JP2018568426A JP2018568426A JP2019519581A5 JP 2019519581 A5 JP2019519581 A5 JP 2019519581A5 JP 2018568426 A JP2018568426 A JP 2018568426A JP 2018568426 A JP2018568426 A JP 2018568426A JP 2019519581 A5 JP2019519581 A5 JP 2019519581A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- modified release
- release solid
- oral formulation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 claims 49
- 239000000203 mixture Substances 0.000 claims 44
- 238000009472 formulation Methods 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 14
- 238000002360 preparation method Methods 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 239000010410 layer Substances 0.000 claims 7
- 239000006186 oral dosage form Substances 0.000 claims 6
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 5
- 239000011247 coating layer Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229920001519 homopolymer Polymers 0.000 claims 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 5
- 238000009498 subcoating Methods 0.000 claims 5
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 4
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 4
- 229920002678 cellulose Chemical class 0.000 claims 4
- 239000001913 cellulose Chemical class 0.000 claims 4
- 235000010980 cellulose Nutrition 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 206010043207 temporal arteritis Diseases 0.000 claims 3
- ISBHMJZRKAFTGE-ONEGZZNKSA-N (e)-pent-2-enenitrile Chemical compound CC\C=C\C#N ISBHMJZRKAFTGE-ONEGZZNKSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical group COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 239000007884 disintegrant Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 239000004014 plasticizer Substances 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 claims 1
- LCFFREMLXLZNHE-RUZDIDTESA-N 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound CC(C)(C=C(C#N)C(=O)N1CCC[C@H](C1)n1nc(-c2ccc(Oc3ccccc3)cc2F)c2c(N)ncnc12)N1CCN(CC1)C1COC1 LCFFREMLXLZNHE-RUZDIDTESA-N 0.000 claims 1
- LCFFREMLXLZNHE-VWLOTQADSA-N 2-[(3s)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@H]2CCCN(C2)C(=O)C(C#N)=CC(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-VWLOTQADSA-N 0.000 claims 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- RWHRFHQRVDUPIK-UHFFFAOYSA-N 50867-57-7 Chemical compound CC(=C)C(O)=O.CC(=C)C(O)=O RWHRFHQRVDUPIK-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 208000032194 Acute haemorrhagic leukoencephalitis Diseases 0.000 claims 1
- 208000008822 Ankylosis Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- MWAPCVRIQHXPBI-UHFFFAOYSA-N CC(C=CC#N)(C)N1CCN(CC1)C1COC1 Chemical compound CC(C=CC#N)(C)N1CCN(CC1)C1COC1 MWAPCVRIQHXPBI-UHFFFAOYSA-N 0.000 claims 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010023198 Joint ankylosis Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000002740 Muscle Rigidity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010071579 Neuronal neuropathy Diseases 0.000 claims 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 206010048705 Paraneoplastic cerebellar degeneration Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 206010071578 autoimmune retinopathy Diseases 0.000 claims 1
- 230000003376 axonal effect Effects 0.000 claims 1
- 206010003882 axonal neuropathy Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 125000005591 trimellitate group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356345P | 2016-06-29 | 2016-06-29 | |
| US62/356,345 | 2016-06-29 | ||
| PCT/US2017/040075 WO2018005849A1 (en) | 2016-06-29 | 2017-06-29 | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519581A JP2019519581A (ja) | 2019-07-11 |
| JP2019519581A5 true JP2019519581A5 (https=) | 2020-08-13 |
| JP7129704B2 JP7129704B2 (ja) | 2022-09-02 |
Family
ID=59315766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568426A Active JP7129704B2 (ja) | 2016-06-29 | 2017-06-29 | ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペント－２－エネニトリルの放出調節製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20190231784A1 (https=) |
| EP (1) | EP3478273A1 (https=) |
| JP (1) | JP7129704B2 (https=) |
| KR (2) | KR102391693B1 (https=) |
| CN (2) | CN115054586B (https=) |
| AU (2) | AU2017290354C1 (https=) |
| CA (1) | CA3028169C (https=) |
| EA (1) | EA201892836A1 (https=) |
| IL (2) | IL263815B (https=) |
| MA (1) | MA45547A (https=) |
| MX (2) | MX390619B (https=) |
| SG (1) | SG11201811255WA (https=) |
| WO (1) | WO2018005849A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2892900T1 (en) | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN115054586B (zh) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| KR20210038877A (ko) | 2018-07-25 | 2021-04-08 | 노파르티스 아게 | Nlrp3 인플라마좀 억제제 |
| WO2020119785A1 (zh) | 2018-12-14 | 2020-06-18 | 正大天晴药业集团股份有限公司 | 一种Syk抑制剂的盐及其结晶型 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| KR20220079909A (ko) | 2019-10-09 | 2022-06-14 | 프린시피아 바이오파마, 인코퍼레이티드 | (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 천포창을 치료하는 방법 |
| US20210106584A1 (en) | 2019-10-14 | 2021-04-15 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| BR112022011950A2 (pt) * | 2020-01-06 | 2022-09-06 | Principia Biopharma Inc | Tratamento da nefropatia membranosa, doença relacionada ao igg4, e síndrome antifosfolipídica usando o inibidor btk 2-[(3r)-3-[4-4-amino-3-(2-fluoro-4-4-fenoxi-fenil)pirazolo[3], 4-4-d]pyrimidin-1-yl]piperidina-1-carbonil]-4-4-metil-4-4-[4-4-(oxetan-3-yl)piperazin-1-il]pent-2-enenitrila |
| AU2021205248A1 (en) * | 2020-01-08 | 2022-09-01 | Principia Biopharma Inc. | Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile |
| US11814390B2 (en) | 2020-01-22 | 2023-11-14 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2022033460A1 (zh) * | 2020-08-10 | 2022-02-17 | 江苏恒瑞医药股份有限公司 | Btk抑制剂治疗疾病的用途 |
| JP7545570B2 (ja) | 2020-08-14 | 2024-09-04 | ノバルティス アーゲー | ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用 |
| EP4322957A1 (en) | 2021-04-16 | 2024-02-21 | Principia Biopharma Inc. | Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds |
| US20260000620A1 (en) * | 2022-01-13 | 2026-01-01 | Amryt Endo, Inc. | Oral dosage forms |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| KR20250088633A (ko) | 2022-10-31 | 2025-06-17 | 프린시피아 바이오파마, 인코퍼레이티드 | (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을투여하여 면역 혈소판 감소증을 치료하는 방법 |
| AU2023390489A1 (en) | 2022-12-09 | 2025-07-24 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia in subjects with cognitive impairment by administering rilzabrutinib |
| WO2025006680A1 (en) | 2023-06-30 | 2025-01-02 | Principia Biopharma Inc. | Methods for treating persistent or chronic immune thrombocytopenia in children, adolescents and adults by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy- phenyl)pyrazolo[3,4-d]pyrimidin-l-yl]piperidine-l-carbonyl]-4- methyl-4-[4-(oxetan-3-yl)piperazin-l-yl]pent-2-enenitrile |
| KR20260040446A (ko) | 2023-07-17 | 2026-03-24 | 카드몬 코포레이션, 엘엘씨 | Btk 저해제 및 벨루모수딜을 포함하는 병용 요법 |
| TW202535404A (zh) | 2023-10-25 | 2025-09-16 | 美商普林斯匹亞生物製藥公司 | 使用ｂｔｋ抑制劑２－［（３ｒ）－３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療與異位性皮炎和／或結節性癢疹相關的搔癢 |
| TW202539683A (zh) | 2023-12-06 | 2025-10-16 | 美商普林斯匹亞生物製藥公司 | 透過投予（ｒ）－２［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４－［４－（氧雜環丁烷－３－基）哌𠯤－１－基］戊－２－烯腈治療中度至重度氣喘 |
| TW202602449A (zh) * | 2024-03-19 | 2026-01-16 | 美商普林斯匹亞生物製藥公司 | ２－［（３ｒ）－２－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑並［３，４－ｄ］嘧啶－１－基］哌啶－１－羰基］－４－甲基－４［４－（氧雜環丁烷－３－基）哌－１－基］－戊－２－烯腈的調配物 |
| WO2026024765A1 (en) | 2024-07-23 | 2026-01-29 | Principia Biopharma Inc. | Treatment of venous thrombosis with rilzabrutinib and derivatives thereof |
| WO2026024885A1 (en) | 2024-07-24 | 2026-01-29 | Principia Biopharma Inc. | Rilzabrutinib for treating warm antibody autoimmune hemolytic anemia |
| WO2026035812A1 (en) | 2024-08-08 | 2026-02-12 | Principia Biopharma Inc. | Methods for treating sickle cell disease by administering a btk inhibitor |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
| DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
| JPS5663950A (en) | 1979-10-30 | 1981-05-30 | Mitsubishi Chem Ind Ltd | Cyclopropanecarboxylic ester |
| FR2535721A1 (fr) | 1982-11-08 | 1984-05-11 | Sanofi Sa | Derives de la piperidinedione protecteurs du myocarde presentant une acticite antiarythmique, leur procede de preparation et les medicaments qui contiennent lesdits derives |
| JPH021450Y2 (https=) | 1984-09-27 | 1990-01-16 | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
| JP2518353B2 (ja) | 1988-06-09 | 1996-07-24 | 住友化学工業株式会社 | シアノ酢酸アミド誘導体およびその製造中間体 |
| CA2018801C (en) | 1990-06-12 | 2000-08-22 | Pierre Louis Beaulieu | Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus |
| JPH04177244A (ja) | 1990-11-10 | 1992-06-24 | Konica Corp | ハロゲン化銀写真感光材料 |
| CA2033447C (en) | 1990-12-31 | 1999-08-31 | Robert Deziel | Synergistic combination for treating herpes infections |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| JPH05301838A (ja) | 1991-10-15 | 1993-11-16 | Mitsubishi Kasei Corp | スチレン誘導体 |
| US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| JPH0827090A (ja) | 1994-05-13 | 1996-01-30 | Sumitomo Chem Co Ltd | シアノ酢酸アミド誘導体、その用途およびその製造中間体 |
| US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
| DE59808284D1 (de) | 1997-03-14 | 2003-06-12 | Basf Ag | Cycloalkylalkancarbonsäureamide, deren herstellung und verwendung |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| IL125947A0 (en) | 1997-09-17 | 1999-04-11 | American Cyanamid Co | 3-(1,2-benzisothiazol- and isoxazol-5-yl)-2,4(1h,3h)-pyrimidinedione or thione and 3-(1,2-benzisothiazol- and isoxazol-5-yl)-4(3)-pyrimidinone or thione herbicidal agents |
| JP2001519379A (ja) | 1997-10-09 | 2001-10-23 | ペリオ、プロダクツ、リミテッド | 遅延性総放出胃腸薬物送達システム |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| EP1169038B9 (en) | 1999-04-15 | 2013-07-10 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| JP2003509428A (ja) | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| AU2000240570A1 (en) | 2000-03-29 | 2001-10-08 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| JP3991812B2 (ja) | 2001-12-11 | 2007-10-17 | 住友化学株式会社 | エステル化合物およびその用途 |
| WO2003068157A2 (en) | 2002-02-11 | 2003-08-21 | The Brigham And Women's Hospital, Inc. | Kinase inhibitors and methods of use thereof |
| NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
| FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0219024D0 (en) | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| JP3955523B2 (ja) | 2002-11-27 | 2007-08-08 | 日立建機株式会社 | 垂直度計および多段伸縮式アーム作業機 |
| MXPA05008878A (es) | 2003-02-21 | 2005-10-05 | Pfizer | Derivados de aminotiazol sustituidos con cicloalquilo que contiene n y composiciones farmaceuticas para inhibir la proliferacion celular, y metodos para su uso. |
| WO2004100868A2 (en) | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
| WO2005011812A1 (en) | 2003-08-01 | 2005-02-10 | Chugai Seiyaku Kabushiki Kaisha | Cyanoamide compounds useful as malonyl-coa decarboxylase inhibithors |
| MXPA06002455A (es) | 2003-09-02 | 2006-08-31 | Pfizer Prod Inc | Formas de dosificacion de liberacion sostenida de ziprasidona. |
| WO2005023773A1 (en) | 2003-09-04 | 2005-03-17 | Pfizer Limited | Process for the preparation of substituted aryl pyrazoles |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| CA2539976A1 (en) | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Therapeutic beta aminoacids |
| JP2007520559A (ja) | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| JP4552456B2 (ja) | 2004-02-27 | 2010-09-29 | 住友化学株式会社 | エステル化合物およびその用途 |
| JPWO2005085210A1 (ja) | 2004-03-10 | 2008-01-17 | 小野薬品工業株式会社 | ニトリル化合物およびその化合物を有効成分として含有する医薬組成物 |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| US7807719B2 (en) | 2004-09-14 | 2010-10-05 | Chaim Roifman | Compounds useful for modulating abnormal cell proliferation |
| JP2008514635A (ja) | 2004-09-27 | 2008-05-08 | コーザン バイオサイエンシス インコーポレイテッド | 特異的キナーゼ阻害剤 |
| AU2006213746A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods |
| WO2006103661A2 (en) | 2005-03-28 | 2006-10-05 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| CA2618646A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
| CN101228134A (zh) | 2005-06-15 | 2008-07-23 | 辉瑞有限公司 | 用作杀寄生虫剂的取代芳基吡唑 |
| US20080176865A1 (en) | 2005-06-15 | 2008-07-24 | Pfizer Limited | Substituted arylpyrazoles |
| US20070149464A1 (en) | 2005-06-15 | 2007-06-28 | Pfizer Inc. | Combination |
| US20080146643A1 (en) | 2005-06-15 | 2008-06-19 | Pfizer Limited | Combination |
| US7645786B2 (en) | 2005-06-15 | 2010-01-12 | Pfizer Inc. | Substituted arylpyrazoles |
| GB0517205D0 (en) * | 2005-08-22 | 2005-09-28 | Novartis Ag | Organic compounds |
| JP5222561B2 (ja) | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| WO2007064932A2 (en) | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc. | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| KR20080098490A (ko) | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
| RU2456265C2 (ru) | 2006-03-31 | 2012-07-20 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам |
| US7645748B2 (en) | 2006-04-03 | 2010-01-12 | Forbes Medi-Tech Inc. | Sterol/stanol phosphorylnitroderivatives and use thereof |
| EP2700638A1 (en) | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
| US20100292229A1 (en) | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
| ATE523499T1 (de) | 2006-07-06 | 2011-09-15 | Array Biopharma Inc | Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| KR20090086080A (ko) | 2006-11-23 | 2009-08-10 | 노파르티스 아게 | 피리미딘 및 그의 ｃｘｃｒ2 수용체 길항제로서의 용도 |
| CN101730699A (zh) | 2007-03-21 | 2010-06-09 | 百时美施贵宝公司 | 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物 |
| GB2447933A (en) | 2007-03-27 | 2008-10-01 | Chemence Ltd | Cyanoacrylate monomer for forming an adhesive polymer |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| CA2712507A1 (en) | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| JP5368485B2 (ja) | 2008-02-25 | 2013-12-18 | エフ．ホフマン−ラ ロシュ アーゲー | ピロロピラジンキナーゼインヒビター |
| KR101324804B1 (ko) | 2008-05-13 | 2013-11-01 | 아이알엠 엘엘씨 | 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물 |
| CA2724715A1 (en) | 2008-05-22 | 2009-11-26 | Amgen Inc. | Heterocycles as protein kinase inhibitors |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| JP2011529918A (ja) | 2008-08-01 | 2011-12-15 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ３阻害剤としてのピペリジン誘導体 |
| US8450337B2 (en) | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
| US20120028981A1 (en) | 2008-11-05 | 2012-02-02 | Principia Biopharma Inc. | Kinase Knockdown Via Electrophilically Enhanced Inhibitors |
| US20100113520A1 (en) | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| JP2013504325A (ja) | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス， インコーポレイテッド | Ｐｉ３キナーゼインヒビターおよびその使用 |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| US20130035325A1 (en) | 2009-11-16 | 2013-02-07 | The Regents Of The University Of California | Kinase inhibitors |
| MX2012013378A (es) | 2010-05-20 | 2013-01-24 | Hoffmann La Roche | Derivados de pirrolo [2, 3-b] pirazina-7-carboxamida y sus uso como inhibidores de cinasa janus (jak) y cinasa tirosina del brazo (syk). |
| TWI500617B (zh) | 2010-05-31 | 2015-09-21 | Ono Pharmaceutical Co | Purine ketone derivatives |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| CN101880243A (zh) | 2010-06-04 | 2010-11-10 | 贵阳柏丝特化工有限公司 | 一种含氟氰拟除虫菊酯化合物及其合成方法与用途 |
| MX336875B (es) | 2010-08-10 | 2016-02-04 | Celgene Avilomics Res Inc | Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk). |
| EP2635284B1 (en) | 2010-11-01 | 2019-12-18 | Celgene CAR LLC | Heterocyclic compounds and uses thereof |
| US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
| WO2012158795A1 (en) | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
| PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| US8828426B2 (en) * | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
| MX2014000130A (es) | 2011-06-28 | 2014-05-01 | Pharmacyclics Inc | Procedimientos y composiciones para la inhibicion de resorcion osea. |
| JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| EP3689878B1 (en) | 2011-07-19 | 2021-10-06 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| CA2841887A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| CN103874699A (zh) | 2011-09-20 | 2014-06-18 | 赛尔佐姆有限公司 | 吡唑并[4,3-c]吡啶衍生物作为激酶抑制剂 |
| MX391121B (es) | 2011-10-19 | 2025-03-19 | Pharmacyclics Llc | Uso de inhibidores de la tirosina cinasa de bruton (btk). |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| KR20210033067A (ko) | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| US9353087B2 (en) | 2012-06-08 | 2016-05-31 | Biogen Ma Inc. | Inhibitors of Bruton's tyrosine kinase |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| US20150140085A1 (en) | 2012-06-29 | 2015-05-21 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| WO2014016754A2 (en) * | 2012-07-26 | 2014-01-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
| WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| SI2892900T1 (en) * | 2012-09-10 | 2018-01-31 | Principia Biopharma Inc. | Pyrazolopyrimidine compounds as kinase inhibitors |
| KR101668574B1 (ko) | 2012-11-02 | 2016-10-24 | 화이자 인코포레이티드 | 브루톤 티로신 키나제 억제제 |
| TW201427664A (zh) | 2012-11-02 | 2014-07-16 | Pharmacyclics Inc | Ｔｅｃ家族激酶抑制劑佐劑療法 |
| EA201590855A1 (ru) | 2012-11-15 | 2015-11-30 | Фармасайкликс, Инк. | Соединения пирролопиримидина как ингибиторы киназ |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| CN105007940B (zh) * | 2012-12-20 | 2017-08-25 | 宾夕法尼亚州研究基金会 | 与癌症治疗相关的方法和组合物 |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| JPWO2014171542A1 (ja) * | 2013-04-19 | 2017-02-23 | 武田薬品工業株式会社 | 放出制御製剤 |
| WO2015132799A2 (en) | 2014-02-03 | 2015-09-11 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
| SG11201704808VA (en) | 2014-12-18 | 2017-07-28 | Principia Biopharma Inc | Treatment of pemphigus |
| US20180193274A1 (en) | 2014-12-24 | 2018-07-12 | Principia Biopharma Inc. | Compositions for ileo-jejunal drug delivery |
| PT3236953T (pt) | 2014-12-24 | 2021-01-29 | Principia Biopharma Inc | Dosagem específica de sítio de um inibidor de btk |
| UA124090C2 (uk) | 2015-06-03 | 2021-07-21 | Прінсіпіа Байофарма Інк. | Інгібітори тирозинкінази |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN105753863B (zh) | 2015-09-11 | 2018-07-31 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
| EP3414234B1 (en) | 2015-10-14 | 2022-06-29 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| CN115054586B (zh) | 2016-06-29 | 2024-08-02 | 普林斯匹亚生物制药公司 | 改性的释放制剂 |
| WO2019208805A1 (ja) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| CN110483521B (zh) | 2018-05-14 | 2022-06-07 | 杭州和正医药有限公司 | 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用 |
| US20210106584A1 (en) | 2019-10-14 | 2021-04-15 | Principia Biopharma Inc. | Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| US11814390B2 (en) | 2020-01-22 | 2023-11-14 | Principia Biopharma Inc. | Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
-
2017
- 2017-06-29 CN CN202210686970.6A patent/CN115054586B/zh active Active
- 2017-06-29 WO PCT/US2017/040075 patent/WO2018005849A1/en not_active Ceased
- 2017-06-29 CN CN201780049475.1A patent/CN109600989B/zh active Active
- 2017-06-29 JP JP2018568426A patent/JP7129704B2/ja active Active
- 2017-06-29 IL IL263815A patent/IL263815B/en unknown
- 2017-06-29 US US16/312,258 patent/US20190231784A1/en not_active Abandoned
- 2017-06-29 CA CA3028169A patent/CA3028169C/en active Active
- 2017-06-29 SG SG11201811255WA patent/SG11201811255WA/en unknown
- 2017-06-29 AU AU2017290354A patent/AU2017290354C1/en active Active
- 2017-06-29 IL IL293621A patent/IL293621B2/en unknown
- 2017-06-29 MA MA045547A patent/MA45547A/fr unknown
- 2017-06-29 MX MX2018016056A patent/MX390619B/es unknown
- 2017-06-29 KR KR1020197002895A patent/KR102391693B1/ko active Active
- 2017-06-29 EA EA201892836A patent/EA201892836A1/ru unknown
- 2017-06-29 EP EP17738009.4A patent/EP3478273A1/en active Pending
- 2017-06-29 KR KR1020227013784A patent/KR102515813B1/ko active Active
-
2018
- 2018-12-18 MX MX2022002952A patent/MX2022002952A/es unknown
-
2020
- 2020-10-28 US US17/082,747 patent/US11872229B2/en active Active
-
2023
- 2023-03-17 AU AU2023201685A patent/AU2023201685A1/en not_active Abandoned
- 2023-12-01 US US18/526,225 patent/US12336999B2/en active Active
-
2025
- 2025-05-23 US US19/217,161 patent/US20250381193A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519581A5 (https=) | ||
| EP3236943B1 (en) | Compositions for ileo-jejunal drug delivery | |
| CN105848647B (zh) | 包含azd9291的药用组合物 | |
| US20190328672A1 (en) | Solid pharmaceutical compositions and processes for their production | |
| MX2012011022A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
| WO2010064126A2 (en) | Controlled release dosage forms | |
| WO2015156581A1 (ko) | 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법 | |
| CN113018273B (zh) | 一种固体制剂及其制备方法和用途 | |
| JP6316422B2 (ja) | フィンゴリモドの医薬組成物 | |
| US11331273B2 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| WO2019203752A2 (en) | Combinations comprising a skeletal muscle relaxant agent and a multiple sclerosis treating agent | |
| US11576917B2 (en) | Pharmaceutical compositions comprising Ibrutinib | |
| US20180064653A1 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| US9561242B2 (en) | Doxycycline composition | |
| US20190240143A1 (en) | Sustained Release Pharmaceutical Dosage Form of Entecavir | |
| CN107205947B (zh) | 用于治疗胃肠道疾病的药物组合物 | |
| EP3796908A1 (en) | Controlled release propiverine formulations | |
| CA2988267A1 (en) | Extended release capecitabine capsules | |
| WO2013054178A2 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
| JP6303045B1 (ja) | 攪拌造粒法を用いたイミダフェナシンを含有する製剤の製造方法 | |
| US9566287B2 (en) | Pharmaceutical composition of doxycycline with reduced food effect | |
| KR102330953B1 (ko) | 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태 | |
| NZ789748B2 (en) | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile | |
| US20060257483A1 (en) | Controlled release bupropion dosage forms | |
| WO2026062565A1 (en) | Oral extended-release dosage form of 7- methylxanthine (7-mx) for the treatment of myopia |